Business, energy, technology, markets and global industry news from Business News Today

biologics

PharmaDeviceNews biologics
Representative image: Biologic vial and infusion setup for multiple sclerosis care, highlighting Teva Pharmaceutical Industries’ Polpharma Biologics deal for a proposed ocrelizumab biosimilar.
Pharma & Biotech

Teva and Polpharma Biologics sign global ocrelizumab biosimilar licensing deal

Teva Pharmaceutical Industries Ltd. has secured exclusive global commercialization rights to Polpharma Biologics’ proposed biosimilar to Ocrevus ocrelizumab for multiple sclerosis, covering both intravenous and subcutaneous formulations upon regulatory approval. Polpharma Biologics will remain responsible for development and manufacturing, while Teva will handle regulatory submissions and commercialization across major markets including the United States, Europe,

Read More
Pharma & Biotech

Could Absci’s ABS-201 open a new biologic pathway for androgenetic alopecia treatment?

Absci’s interim ABS-201 data strengthen the early case for a long-acting PRLR antibody in androgenetic alopecia and AI-designed biologics.

Read More
Representative biotech patent litigation image showing antibody discovery research, laboratory documents and legal symbols.
Pharma & Biotech

Could Harbour BioMed’s legal win reshape the economics of antibody drug discovery?

Read how Harbour BioMed’s Amgen patent win could reshape antibody discovery licensing, biologics IP and biotech investor sentiment.

Read More
Representative image: A dermatologist discusses plaque psoriasis treatment with a patient, reflecting Akeso’s gumokimab approval and the intensifying IL-17 biologics race in China’s autoimmune disease market.
Pharma & Biotech

Why Akeso’s gumokimab approval could sharpen China’s psoriasis biologics race

Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and IL-17 competition.

Read More
Representative image: A dermatologist examines an eczema flare, reflecting how EBGLYSS and other atopic dermatitis biologics are shifting the treatment conversation toward fewer injections, longer disease control, and lower patient burden.
Features & Analysis

How EBGLYSS shows the eczema market is moving from breakthrough launches to lifecycle strategy

Find out why fewer injections and longer disease control are becoming key battlegrounds in eczema biologics and dermatology care.

Read More
Representative image of a modern biologics manufacturing facility. Aurobindo Pharma’s TheraNym Biologics launch highlights India’s push into high-capacity CDMO infrastructure, advanced bioreactor manufacturing, and global biologics outsourcing.
Pharma & Biotech

Aurobindo Pharma launches TheraNym as MSD anchor deal strengthens biologics CDMO push

Find out how Aurobindo Pharma’s TheraNym launch could reshape India’s biologics CDMO ambitions and investor sentiment.

Read More
Pharma & Biotech

Can RenSuper help Biocytogen reduce the bottlenecks in antibody development?

Biocytogen is turning antibody discovery into an AI-led industrial workflow. RenSuper could speed biologics R&D, but validation risk remains.

Read More
Features & Analysis

Drug discovery has an AI problem. Clicklinks thinks the answer is connection, not just algorithms

Find out how Sanyou Bio’s Clicklinks platform could reshape AI-led drug discovery by linking biotech, CRO, CDMO and preclinical resources.

Read More
Representative image of biosimilar development and biologics manufacturing for autoimmune disease treatment, highlighting the Polpharma Biologics and Tuteur licensing deal to expand affordable therapy access across Latin America.
Pharma & Biotech

Can Polpharma Biologics and Tuteur improve access to autoimmune disease biologics in Latin America?

LATAM autoimmune care needs cheaper biologics. Polpharma Biologics and Tuteur are betting a biosimilar deal can shift access.

Read More
Pharma & Biotech

Kexing Biopharm leans on IQVIA as biosimilar competition moves from China to global markets

Biosimilars need speed, but regulators still demand proof. IQVIA and Kexing test whether AI can cut friction without cutting evidence.

Read More